Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan

Pin-Chun Chen1,2☯, Yuan-Chi Lee2,3,4☯, Yu-Chieh Su4,5, Cheng-Hung Lee6,7, Jian-Han Chen3,4,8‡*, Chung-Yen Chen3,4,8‡

1 Division of Colon & Rectal Surgery, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan, 2 Division of General Surgery, E-Da Da-Chang Hospital, Kaohsiung, Taiwan, 3 Division of General Surgery, E-Da Hospital, Kaohsiung, Taiwan, 4 School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan, 5 Division of Hematology-Oncology, E-Da Hospital, Kaohsiung, Taiwan, 6 Department of General Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, 7 School of Medicine, Tzu Chi University, Hualien, Taiwan, 8 Bariatric and Metabolism International Surgery Center, E-Da Hospital, Kaohsiung, Taiwan

☯ These authors contributed equally to this work.
‡ JH Chen and CY Chen are co-corresponding authors
* jamihan1981@gmail.com

Abstract

Background
Liver metastases from breast cancer are associated with poor prognosis, and treatment options are usually restricted to palliative systemic therapy. The impact of liver resection on metastasis remains controversial. The aim of this study is to investigate whether liver resection can offer better survival outcomes in cases of isolated liver metastases from breast cancer.

Methods
We conducted a nationwide cohort study using a claims dataset from Taiwan’s National Health Insurance Research Database (NHIRD). We identified all patients with breast cancer (diagnostic code ICD-9: 174.x) from the Registry for Catastrophic Illness Patient Database (RCIPD) of the NHIRD who underwent mastectomy between January 1, 2000, and December 31, 2008. Patients with other malignancies (history, initially, or during follow-up), those with a history of metastasis prior to or at initial admission for mastectomy, and those without liver metastases were excluded. Patients with other metastases between mastectomy and liver metastasis and those who died at first admission for liver resection were also excluded. All patients were followed up until December 31, 2013, or withdraw from the database because of death.

Results
Data were analyzed for 1,116 patients who fulfilled the inclusion criteria (resection group: 89; non-resection group: 1,027). There were no differences in age, Charlson Comorbidity...
Index, or major coexisting diseases except renal disease between two groups. Kaplan–Meier analysis demonstrated that the liver resection group had significantly better overall survival (OS) than the non-resection group. (1-year: 96.6% vs. 52.3%, 2-year: 86.8% vs. 35.4%, 3-year: 72.3% vs. 25.2%, 5-year: 51.6% vs. 16.9%, respectively, p<0.001). Cox analysis revealed that the liver resection group exhibited a significant improvement in patient survival (hazard ratio [HR] = 0.321, 95% confidence interval [CI]: 0.234–0.440, p<0.001).

Conclusion
These findings indicate that liver resection may offer better survival benefit in patients with breast cancer who develop new liver metastases post mastectomy.

Introduction
Breast cancer is the second leading cause of cancer-related death in women worldwide [1] and the number of cases is increasing annually. Metastasis is present in many cases of breast cancer. Liver metastases (BCLM) develop in approximately 50% of all patients with metastatic breast cancer, representing the primary site of breast cancer recurrence in 5–12% [2]. BCLM is viewed as a disseminated disease, and the standard treatment focuses on systemic therapies and palliative local treatment [3]. In addition, metastatic breast cancer can lead to resistance to therapy and shorter overall survival. Thus, BCLM exhibit one of the worst prognoses among all types of breast cancer metastases [4]. Previous studies have reported that the median survival for BCLM is only 3–15 months, with a 5-year survival rate of only 0–12% [4–6]. BCLM has long been considered a systemic disease that requires only chemotherapy and optimal supportive care without surgical intervention [7,8]. With the advent of new chemotherapeutic agents and interventions other than hepatectomy (e.g., transarterial chemoembolization [TACE], hepatic arterial infusion chemotherapy [HAIC], and radiofrequency ablation [RFA]), hepatectomy appears to play a minor role in BCLM.

Surgical resection is a potentially curative treatment and is beneficial for overall survival patients with stage IV colorectal and neuroendocrine cancers who have developed liver metastases [9–11]. Previous studies have reported favorable outcomes in patients with breast cancer who underwent resection of brain [12,13] and bone metastases [14]. Hence, surgical resection may be a promising treatment option in cases of breast cancer with liver metastases (BCLM) [15]. Recent studies have demonstrated that liver resection can improve survival beyond 5 or 10 years after BCLM surgery [16–19].

There is no global consensus on whether liver resection is beneficial for patients with BCLM. The 5th European School of Oncology–European Society of Medical Oncology (ESO–ESMO) International Consensus Guidelines for Advanced Breast Cancer (ABC 5) suggest that liver resection for BCLM can be considered in select patients [20] who exhibit good performance status and have a limited tumor burden. However, the National Comprehensive Cancer Network (NCCN) guidelines do not mention liver resection as an option for BCLM [21]. Thus, the long-term survival benefit of hepatectomy for BCLM remains controversial.

In this cohort study, we extracted data from Taiwan’s National Health Insurance Research Database (NHIRD) to assess the long-term effects of hepatectomy on survival in patients with BCLM. The null hypothesis is that hepatectomy did not offer survival benefit for BCLM compared to non-surgical treatment.
Methods

Database and study sample

The National Health Insurance (NHI) program was launched in Taiwan in 1995 and includes contracts with 97% of medical providers, covering approximately 23 million beneficiaries [22]. The National Health Insurance Research Database (NHIRD; registration number NHIRD-103-246) includes all claims data for beneficiaries and uses International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to record diagnoses [23]. This study was fully evaluated and approved by the Institutional Review Board of Da-lin Hospital (B10503009). All procedures performed in studies involving human participants followed the ethical standards of the institutional and national research committee and were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived given the nature of the study.

Inclusion and exclusion criteria

We extracted data for all female patients with breast cancer (ICD-9 code: 174.x) diagnosed between January 1, 1996, and December 31, 2013, from the Registry for Catastrophic Illness Patient Database (RCIPD) of the NHIRD [24]. The RCIPD includes relatively accurate data regarding breast cancer diagnoses because pathological confirmation of breast cancer after surgery is required for patients to be registered. Based on inpatient expenditures (DD), we then identified all patients with diagnostic codes for breast cancer who had been admitted between January 1, 2000, and December 31, 2008, and had undergone mastectomy (partial mastectomy, ICD-9 procedure codes: 85.21 to 85.25; subcutaneous total mastectomy, ICD-9 procedure codes: 85.33 to 85.36; unilateral total mastectomy, ICD-9 procedure codes: 85.41, 85.43, 85.45, 85.47; and bilateral total mastectomy, ICD-9 procedure codes: 85.42, 85.44, 85.46, 85.48). We included patients who were admitted with the diagnostic code for liver metastasis (ICD-9 code: 197.7) after mastectomy for further analysis.

We excluded patients with metastasis before or at the time of mastectomy. We also excluded patients who had other malignancies or any metastasis before or during the follow-up period between mastectomy and the primary endpoint. Furthermore, patients who died during the first admission for liver metastasis were also excluded. All included patients were separated into two groups based on whether they underwent liver resection. The liver resection group included patients with ICD-9 procedure codes of 50.29 or 50.3, while the non-resection group included the remaining patients. The selection algorithm is illustrated in **Fig 1**.

Index date and primary end points

The first admission date with liver metastasis was defined as the date of liver metastasis, which was regarded as the index date in this study. The primary endpoint was patient death, the date of which was identified using the RCIPD. If the date of death was not available in the RCIPD, death was defined as withdrawal from the NHI program [24]. All included patients were followed up until death or the end of the study period (December 31, 2013).

Covariate assessment

Comorbidities (identified by ICD codes) were recorded in the NHIRD 1 year before the index date. Health status was assessed using the Charlson Comorbidity Index (CCI) [25,26]. Comorbidities used as covariates included diabetes mellitus (250), hypertension (401–405), liver
disease (571.2, 571.4–6, 572.2–8, 456.0–456.21), renal disease (582, 583, 585, 586, and 588), peptic ulcer disease (531–534), chronic pulmonary disease (490–496, 500–505, 506.4), cerebrovascular disease (430–438), and myocardial infarction (410, 412).

**Statistical analysis**

SPSS software (IBM, Chicago, IL, USA, Statistics 24 version) was used for the analysis. For basic clinical characteristics and covariates, the chi-square test and Fisher’s exact test were used to compare categorical variables. Continuous variables were analyzed using the Kolmogorov–Smirnov test and then compared using Student’s t-test or the Mann–Whitney U-test, based on the results of the Kolmogorov–Smirnov one-sample test. Kaplan–Meier analyses were used to compare differences in overall survival (OS) after liver metastasis between the liver resection and non-resection groups. We also used a univariable Cox proportional hazards model to evaluate the risk of overall mortality among the different covariates. Variables with a p value less than 0.2 were selected and inserted into the multivariable backward stepwise Cox proportional hazards model. Statistical significance was defined as a two-tailed p value < 0.05.
Results

The analysis included 1,116 patients who developed liver metastases during the follow-up period after mastectomy. The median follow-up duration was 13.08 months. The liver resection and non-resection groups included 89 and 1,027 patients, respectively. The clinical characteristics, comorbidities, and follow-up durations of the two groups are presented in Table 1. Age, CCI values, and rates of major coexisting diseases (except renal disease) were similar between the two groups. The age at which mastectomy was performed, the frequency of total mastectomy, and the duration between mastectomy and liver metastasis were also similar in the two groups. The total follow-up duration was significantly longer in the liver resection group (40.30 ± 35.55 months) than in the non-resection group (10.77 ± 26.50 months). In the resection group, the median length of hospitalization was 9 days, and no mortality was observed.

OS after more than 1 year of follow up

Fig 2 demonstrates the results of the Kaplan–Meier analysis with log-rank testing for overall survival. The liver resection group exhibited significantly better OS after the identification of liver metastasis than the non-resection group. The 1-, 2-, 3-, and 5-year OS rates were 96.60%, 86.80%, 72.30%, and 51.60% in the liver resection group and 52.30%, 35.40%, 25.20%, and 16.90% in the non-resection group ($p < 0.001$).

We included all covariates (age, CCI score, liver resection, and coexisting disease) in the Cox regression model (Table 2). Multivariate analysis revealed that liver resection had a

Table 1. Basic characteristics in the liver resection and non-surgery groups.

| Clinical characteristics | Non-resection group | Liver resection group | p   |
|--------------------------|---------------------|-----------------------|-----|
| Age at liver metastasis (y), median (IQR) | 54.08 (16.42) | 53.75 (17.00) | 0.507 |
| Charlson Comorbidity Index |               |                       | 0.685 |
| Median (IQR)            | 2.00 (0)           | 2.40 (0)              |     |
| Range                   | 0 (0–7)            | 0 (0–4)               |     |
| Follow up after liver metastasis (months) | 10.77 (26.50) | 40.30 (35.55) | <0.001 |
| Age at Mastectomy (y), median (IQR) | 50.67 (16.50) | 51.00 (16.0) | 0.448 |
| Total Mastectomy        | 756 (73.6%)        | 64 (71.9%)            | 0.709 |
| Time to liver metastasis (months) | 34.10 (42.37) | 33.87 (35.90) | 0.409 |
| Time to liver resection |                     |                       |     |
| Median (IQR)            | 5.4 (12.72)        |                      |     |
| Delayed                 | 0.13–48.77         |                      |     |

IQR: Interquartile range; DM: Diabetes mellitus; HTN: Hypertension.

https://doi.org/10.1371/journal.pone.0266960.t001
significant survival benefit for patients with BCLM (hazard ratio [HR] = 0.308, 95% confidence interval [CI]: 0.224–0.424, \(p<0.001\)). Other risk factors for decreased overall survival included older age (HR = 1.008, 95% CI: 1.002–1.014, \(p = 0.014\)), history of hypertension (HR = 1.267, 95% CI: 1.038–1.545, \(p = 0.020\)), cerebrovascular disease (HR = 1.609, 95% CI: 1.085–2.385, \(p = 0.018\)), and myocardial infarction (HR = 3.561, 95% CI: 1.543–8.221, \(p = 0.003\)).

### Discussion

Our nationwide data analysis demonstrated that liver resection is beneficial for patients with BCLM, and that it is associated with relatively favorable long-term survival. The median 1-, 2-

---

**Table 2. Risk factors influencing overall survival after identification of liver metastasis.**

|                     | Univariate analysis |          |          | Multivariate analysis |          |          |
|---------------------|---------------------|----------|----------|-----------------------|----------|----------|
|                     | HR                  | 95% CI   | \(p\)    | HR                    | 95% CI   | \(p\)    |
| **Age**             |                     |          |          |                       |          |          |
|                     | 1.013               | (1.007 -1.019) | <0.001  | 1.008                 | (1.002 -1.014) | 0.014  |
| **CCI**             |                     |          |          |                       |          |          |
|                     | 1.141               | (1.069 -1.218) | <0.001  | 1.013                 | (0.908 -1.130) | 0.816  |
| **Liver resection** | 0.324               | (0.237 -0.444) | <0.001  | 0.308                 | (0.224 -0.424) | <0.001  |
| **Comorbidities**   |                     |          |          |                       |          |          |
| DM                  | 1.308               | (1.048 -1.631) | 0.017  | 1.087                 | (0.857 -1.379) | 0.492  |
| HTN                 | 1.457               | (1.223 -1.736) | <0.001  | 1.267                 | (1.038 -1.545) | 0.020  |
| Liver disease       | 2.427               | (1.007 -5.851) | 0.048  | 1.748                 | (0.717 -4.259) | 0.219  |
| Chronic pulmonary disease | 1.062 | (1.072 -1.607) | 0.777 |
| Cerebrovascular disease | 2.189 | (1.508 -3.176) | <0.001  | 1.609                 | (1.085 -2.385) | 0.018  |
| Myocardial infarction | 3.000 | (1.342 -6.704) | 0.007  | 3.561                 | (1.543 -8.221) | 0.003  |
| Peptic ulcer disease | 1.023               | (0.742 -1.411) | 0.890 |
| Renal disease       | 1.148               | (0.72 -1.831) | 0.563 |

CCI: Charlson Comorbidity Index; CI: Confidence interval; HR: Hazard ratio; DM: diabetes mellitus; HTN: Hypertension.

https://doi.org/10.1371/journal.pone.0266960.t002
3-, and 5-year OS rates were 96.60%, 86.80%, 72.30%, and 51.60% in the resection group and 52.30%, 35.40%, 25.20%, and 16.90% in the non-resection group, respectively (p<0.001). These finding were generally consistent with the available published data (Table 3). Furthermore, we identified several predictors of unfavorable OS in patients with BCLM undergoing hepatectomy, including myocardial infarction, older age, hypertension, and cerebrovascular disease.

Table 3. Survival data of studies investigating surgical resection for BCLM patients.

| Study, Year | Design | Survival rate, % | Overall Survival (mo) (Non-surgery vs. Surgical resection) | Improved Survival Prognostic factors |
|-------------|--------|------------------|-----------------------------------------------------------|-------------------------------------|
| Pocard et al, 2000 [27] | Retrospective, Single institution, n = 52 | 1-Year 86% 3-Year 49% 5-Year NR | 14 vs. 47 months | Interval between primary diagnosis and diagnosis of liver metastasis. (48 months) |
| Elias et al, 2003 [28] | Prospective, Single institution, n = 54 | 1-Year NR 3-Year 50% 5-Year 34% | NR vs. 34.3 months | Positive hormone receptor status |
| Adam et al, 2006 [5] | Prospective, Single institution, n = 85 | 1-Year NR 3-Year NR 5-Year 37% | NR | lack of response to prehepatectomy chemotherapy, The presence of extrahepatic metastases at the time of hepatectomy, R2 resection (negative association) |
| Hoffmann et al, 2010 [29] | Prospective, Single institution, n = 41 | 1-Year NR 3-Year 68% 5-Year 48% | NR vs. 58 months | Disease free interval less than 1 year, Positive resection margin (negative association) |
| Abbott et al, 2012 [30] | Prospective, Single institution, n = 86 | 1-Year NR 3-Year NR 5-Year 45% | NR vs. 57 months | Stable disease; positive estrogen receptor status |
| Kostov et al, 2013 [31] | Prospective, Single institution, n = 42 | 1-Year 84% 3-Year 64% 5-Year 38% | NR vs. 43 months | R0; diameter < 4 cm, Positive hormone receptor status |
| Mariani et al, 2013 [32] | Retrospective, Single institution, n = 51 | 1-Year NR 3-Year 80% 5-Year 50% | NR vs. 91 months | Surgical resection; no extrahepatic disease |
| Bacalbasa et al, 2014 [33] | Prospective, Single institution, n = 43 | 1-Year 93% 3-Year 74% 5-Year 58% | NR vs. 32.2 months | Positive hormone receptor status |
| Margonis et al, 2016 [34] | Retrospective, Multi-institution, n = 131 | 1-Year 98% 3-Year 75% 5-Year NR | NR vs. 53.4 months | Negative surgical margin, Diameter of BCLM (< 3cm) |
| Sadot et al, 2016 [35] | Retrospective, Single institution, n = 69 | 1-Year NR 3-Year NR 5-Year 37% | 30 vs. 53 months | None |
| Ercolini et al, 2018 [36] | Retrospective, Single institution, n = 51 | 1-Year 92% 3-Year 69% 5-Year 36% | NR vs. 51 months | Tumor diameter (< 5cm), R0 resection, Triple-negative tumor (negative association) |
| Labgaa et al, 2018 [37] | Retrospective, Multi-institution, n = 59 | 1-Year 92% 3-Year 74% 5-Year 61% | NR vs. 35 months | Age < 60 years |

(Continued)
BCLM is viewed as a disseminated disease, which was reported with worst prognoses among all types of breast cancer metastases [4]. Previously, the standard treatment focuses on systemic therapies and palliative local treatment [3]. However, previous studies have reported that the median survival for BCLM is only 3–15 months, with a 5-year survival rate of only 8.5% [5,6].

Like our study, hepatectomy can offer a better survival for patients with BCLM, even beyond 5 or 10 years after BCLM surgery [16–19,45]. Ruiz A, et al. presented a case-matched analysis that liver resection for BCLM had an impressive median OS of 82 months when compared to a median OS of 31 months in BCLM patients who only received systemic treatment [38]. Compared to systemic treatment only, patients who underwent liver resection had significantly better mean (61.8 versus 38.6 months), 3-year(54.7% versus 45.6%), and 5-year OS (54.7% versus 21.9%, respectively) by using propensity score matching [46]. These findings are comparable to the results of the present study. In clinical practice, liver metastasectomy represents a possible therapeutic option for select patients with BCLM. In addition to being associated with better long-term outcomes, liver resection was found to be cost-effective in patients with BCLM when compared to systemic therapy alone, particularly in patients with ER-positive tumors or when newer targeted agents were used [47].

There are several factors influencing the survival after liver resection for BCLM. Tumor size also influences the survival rate among patients with BCLM. In a recent multi-institutional study, Margonis et al. analyzed data for 131 patients who underwent liver resection for BCLM between 1980 and 2014. They found that the median survival time for patients with tumors

### Table 3. (Continued)

| Study, Year | Design                        | Survival rate, % | Overall Survival (mo) (Non-surgery vs. Surgical resection) | Improved Survival Prognostic factors |
|-------------|-------------------------------|------------------|-------------------------------------------------------------|--------------------------------------|
| Ruiz et al, 2018 [38] | Retrospective, Single institution. n = 139 | 1-Year NR 31 vs. 82 months | 31 vs. 82 months | Not reported. |
| Sunden et al, 2020 [39] | Prospective, Multi-institution. n = 29 | 1-Year 90% 28 vs. 77 months | Surgical resection, HER2 gene amplification |
| He et al, 2020 [40] | Prospective, Multi-institution. n = 67 | 1-Year 93% NR vs. 57 months | Pringle maneuver, Increased interval between surgical resection and diagnosis of BCLM |
| Chun et al, 2020 [41] | Retrospective, Multi-institution. n = 136 | 1-Year NR 28 vs. 57 months | Breast cancer receptor status |
| Ellis V. et al, 2021 [42] | Retrospective, Multi-institution. n = 98 | 1-Year 91.1% 28.8 vs. 55.2 months | Higher income status (income >$63,000), Insurance coverage, Surgical resection |
| Orlandi et al, 2021 [43] | Retrospective, Multi-institution. n = 22 | 1-Year 100% NR vs. 67 months | Negative resection margin (R0) |
| Procházkov, et al, 2021 [44] | Retrospective, Single institution. n = 30 | 1-Year NR NR vs. 56.3 months | Negative hormone receptor |

*NR: Not reported.*
<3.0 cm was 58.8 months, while that for patients with tumors ≥3.0 cm was 53.3 months (p = 0.041). Multivariate analysis indicated that a positive surgical margin (HR = 3.57, 95% CI: 1.40–9.16; p = 0.008) and a diameter greater than 3 cm (HR = 1.03, 95% CI: 1.01–1.06; p = 0.002) were associated with poorer survival [34]. Although we did not include the size of tumor and the extensive of liver resection for analysis because we cannot obtain these data from the database we used, all patients with BCLM who planned to received liver resection were well evaluated by surgeon. Patients in the resection group may have presented with a more acceptable oncologic burden for surgical resection.

Hormone receptor status is among the key factors considered when determining breast cancer treatment, especially in patients with BCLM [48]. Furthermore, molecular subtypes are not only a predictor of clinical outcomes in patients with BCLM; they are also a risk factor for liver metastasis [49,50]. Recently, a propensity-matched analysis of 136 patients who underwent hepatectomy plus systemic therapy reported that the intrinsic subtype was an independent predictor of poor OS (HR = 4.28) [51]. The median OS after resection among patients with luminal A, luminal B, HER2-enriched, and basal-like subtypes was 53, 75, 81, and 17 months (p<0.001), respectively.

Similarly, the median progression-free survival (PFS) among patients with the HER2-enriched subtype at 60 months was significantly better than that at 17, 16, and 5 months among patients with the luminal A, luminal B, and basal-like subtypes, respectively (p<0.001). After propensity score matching, the 5-year OS was significantly better in the surgical group than in the cohort of patients who had received systemic therapy alone (56% and 40%, p = 0.018). Lack of progesterone (PR) and estrogen receptor (ER) expression is associated with poor OS, as this reduces the response to hormonal therapy [52]. In recent years, however, there have been several important advances in targeting the unique biology of these subtypes, including several HER2 neu-targeted therapies. These subtypes unsurprisingly benefit the most from the resection of BCLM. Unfortunately, in our study, we cannot evaluate these reported finding such as status of hormone therapy and subtypes of tumor cell. The timing, regimen, and dosage of chemotherapy and hormone therapy were not recorded in the database and could not therefore be determined. However, in Taiwan, every patient who had breast cancer will receive chemotherapy, hormone therapy, anti-HER2 therapy and radiotherapies based on different condition. Most of these therapies were supported by national health insurance. Moreover, like previous reported study [16–19,38,45–47], the null hypothesis of our study is that hepatectomy did not offer survival benefit for BCLM compared to non-surgical treatment. Although we did not include these reported risk factor for analysis, we believed that even in patients with metachronous liver metastasis who received aggressive chemotherapy for metastatic gastric cancer, liver resection still had a role.

Recently, locoregional therapies have recently gained attention for their potential in the treatment of patients with BCLM [53]. With the advent of interventional treatments such as TACE, HAIC, and RFA, patients and clinicians have more treatment options. In a meta-analysis of 14 studies, Xiao et al. aimed to compare the therapeutic effectiveness of resection versus ablation among patients with BCLM. A comparison of patients who underwent RFA revealed that hepatic resection was associated with better 5-year OS (odds ratio [OR] = 0.38; 95% CI, 0.32–0.46; p<0.001) and 5-year disease-free survival (OR = 0.51; 95% CI, 0.40–0.66; p<0.001) [54]. Another meta-analysis of 23 studies revealed that hepatic resection resulted in longer median overall survival (mOS) and 5-year survival (45 months, 41%) than RFA (38 months and 11–33%) or TACE (mOS, 19.6 months; 1-year survival: 32–88.8%, n = 8 studies) [55]. In Taiwan, the most indication for RFA was hepatocellular carcinoma. On rare patients with metastatic liver tumor received RFA. Moreover, in the inclusion period of our study, before 2009, RFA for metastatic liver tumor is still debated. Although we did not exclude RFA from non-
resection group, the data we presented still reflects clinical significance in treating BCLM. However, these recent finding showed that a multidisciplinary approach and personalized treatment are important for managing patients with BCLM [48,56,57]. Further studies should aim to clarify which treatment provides the most benefit in patients with BCLM.

**Limitations**

Our study had several limitations. First, some details including the actual initial stage, extension, and pathological characteristics of the primary tumor (e.g., ER, PR, or HER-2 status) and the details of each operation were not recorded and therefore could not be analyzed. Second, some details were not recorded in the database because of their nature, such as the timing, regimen, and dosage of chemotherapy. We were also unable to obtain details when patients received outpatient chemotherapy. Furthermore, in addition to selection bias, miscoding may have occurred since surgeons do not usually use ICD-9 coding but rather different coding and Health Insurance Surgical orders, which they obtain from the Taiwan NHI payment system. However, most ICD-9 codes during admission were assigned by professional coders based on records during admission. In addition, a code table comparing ICD-9 codes and NHI payment system codes is available from the National Health Insurance Administration Ministry of Health and Welfare. We therefore believe that the rate of miscoding for surgical procedures was limited. Moreover, the extent of tumor spread in the liver was not recorded in our database, indicating that patients in the resection group may have had a more acceptable oncologic burden on surgical resection. However, we believe that liver resection still played a role even in patients with metachronous liver metastasis who received aggressive chemotherapy for metastatic breast cancer.

**Conclusion**

The present findings demonstrate that liver resection may offer survival benefit in patients with breast cancer who develop hepatic metastases post mastectomy. Based on our findings, liver resection could be considered as a treatment option for improving the overall survival of such patients. Further studies are required to validate the effectiveness of multidisciplinary approach and personalized treatment for BCLM.

**Acknowledgments**

The authors would like to thank Dr. Yaw-Sen Chen, Division of General Surgery, E-Da Hospital, and Dr. Chao-Ming Hung, Division of General Surgery, E-Da Cancer Hospital for their assistance.

**Author Contributions**

- **Conceptualization:** Cheng-Hung Lee, Jian-Han Chen.
- **Data curation:** Yu-Chieh Su, Jian-Han Chen.
- **Formal analysis:** Cheng-Hung Lee, Jian-Han Chen, Chung-Yen Chen.
- **Methodology:** Yu-Chieh Su, Jian-Han Chen, Chung-Yen Chen.
- **Project administration:** Yu-Chieh Su, Jian-Han Chen, Chung-Yen Chen.
- **Resources:** Cheng-Hung Lee, Jian-Han Chen.
- **Software:** Jian-Han Chen.
- **Validation:** Jian-Han Chen, Chung-Yen Chen.
References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7–30. Epub 2018/01/10. https://doi.org/10.3322/caac.21442 PMID: 29313949.

2. He ZY, Wu SG, Peng F, Zhang Q, Luo Y, Chen M, et al. Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT. Transl Oncol. 2017; 10(1):1–9. Epub 2016/11/27. https://doi.org/10.1016/j.tranon.2016.10.004 PMID: 27898707; PubMed Central PMCID: PMC5123039.

3. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2020; 18(4):452–78. https://doi.org/10.6004/jnccn.2020.0016 PMID: 32259783.

4. Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, et al. Predictive profile-nomogram for liver resection for breast cancer metastases: an aggressive approach with promising results. Annals of surgical oncology. 2017; 24(2):535–45. https://doi.org/10.1245/s10434-016-5522-7 PMID: 27573523.

5. Adam R, Aloia T, Krisat J, Bralet M-P, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Annals of surgery. 2006; 244(6):897. https://doi.org/10.1097/01.sla.0000246847.02058.1b PMID: 17122615.

6. Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast cancer research and treatment. 2006; 97(3):237–44. https://doi.org/10.1007/s10549-005-9117-4 PMID: 16322882.

7. Jardines L, Callans LS, Torosian MH. Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol. 1993; 20(5):538–47. Epub 1993/10/01. PMID: 7692605.

8. Seidman AD. Chemotherapy for advanced breast cancer: a current perspective. Semin Oncol. 1996; 23(1 Suppl 2):55–9. Epub 1996/02/01. PMID: 8614846.

9. Ali SM, Pawlik TM, Rodriguez-Bigas MA, Monson JR, Chang GJ, Larson DW. Timing of surgical resection for curative colorectal cancer with liver metastasis. Annals of surgical oncology. 2018; 25(1):32–7. https://doi.org/10.1245/s10434-016-5745-7 PMID: 28224365.

10. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncologic approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The oncologist. 2012; 17(10):1225. https://doi.org/10.1634/theoncologist.2012-0121 PMID: 22962059.

11. Spolverato G, Bagante F, Wagner D, Buettner S, Gupta R, Kim Y, et al. Quality of life after treatment of neuroendocrine liver metastasis. Journal of surgical research. 2015; 198(1):155–64. https://doi.org/10.1016/j.jss.2015.05.048 PMID: 26095419.

12. Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastases in patients with breast cancer. Annals of surgical oncology. 1997; 4(6):481–90. https://doi.org/10.1007/BF02303672 PMID: 9309337.

13. Wróński M, Arút E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1997; 80(9):1746–54. https://doi.org/10.1002/(sici)1097-0142(19971101)80:9<1746::aid-cncr8>3.0.co;2-c PMID: 9351543.

14. Dürre HR, Müller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clinical Orthopaedics and Related Research®. 2002; 396:191–6. PMID: 11859243.

15. Patkar S, Niyogi D, Parray A, Goel M. Is resection for noncolorectal, nonneuroendocrine liver metastases justified? Journal of Surgical Oncology. 2021; 123(4):957–62. https://doi.org/10.1002/jso.26373 PMID: 33428773.

16. Golse N, Adam R. Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results. Clin Breast Cancer. 2017; 17(4):256–65. Epub 2017/02/16. https://doi.org/10.1016/j.clbc.2016.12.012 PMID: 28196771.
Outcomes of hepatectomy for breast cancer with liver metastasis

17. Ruiz A, Sebagh M, Wicherts DA, Castro-Benitez C, van Hillegersberg R, Paule B, et al. Long-term survival and cure model following liver resection for breast cancer metastases. Breast cancer research and treatment. 2018; 170(1):89–100. https://doi.org/10.1007/s10549-018-4714-1 PMID: 29464535

18. Sundén M, Hermansson C, Taflin H, Andersson A, Sund M, Hemmingsson O. Surgical treatment of breast cancer liver metastases: A nationwide registry-based case control study. European Journal of Surgical Oncology. 2020; 46(6):1006–12. https://doi.org/10.1016/j.ejso.2020.02.008 PMID: 32089734

19. Orlandi A, Pontolillo L, Mele C, Pasqualoni M, Pannunzio S, Cannizzaro MC, et al. Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis. Journal of Personalized Medicine. 2021; 11(3):187. https://doi.org/10.3390/jpm11030187 PMID: 33800160

20. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M, André F, et al. 5th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. 2020; 31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010 PMID: 32979513

21. Gradishar WJ, Moran MS, Abraham J, Alt R, Agnese D, Allison KH, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2021; 19(5):484–93. https://doi.org/10.6004/jnccn.2021.0023 PMID: 34794122

22. Ho Chan W. Taiwan’s healthcare report 2010. The EPMA Journal. 2010; 1(4):563–85. https://doi.org/10.1007/s13167-010-0056-8 PMID: 23199110

23. Chinese Hospital Association. ICD-9-CM English-Chinese Dictionary. Taipei, Taiwan: Chinese Hospital Association Press; 2000.

24. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012; 308(18):1906–14. Epub 2012/11/20. https://doi.org/10.1001/2012.jama.11975 PMID: 23162861.

25. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245–51. Epub 1994/11/01. https://doi.org/10.1016/0895-4356(92)90133-8 PMID: 12559448

26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613–9. Epub 1992/06/01. https://doi.org/10.1016/0895-4356(92)90133-8 PMID: 1607900.

27. Pocard M, Pouillart P, Asselain B, Salmon R-J. Hepatic resection in metastatic breast cancer: results and prognostic factors. European journal of surgical oncology. 2000; 26(2):155–9. https://doi.org/10.1053/ejso.1999.0761 PMID: 10744935

28. Elias D, Maisonnette F, Druet-Cabanac M, Ouellet J-F, Guinebretiere J-M, Spielmann M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. The American journal of surgery. 2003; 185(2):158–64. https://doi.org/10.1016/s0002-9610(02)01204-7 PMID: 12559448

29. Hoffmann K, Franz C, Hinz U, Schirmacher P, Herfarth C, Eichbaum M, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010; 17(6):1546–54. Epub 2010/02/10. https://doi.org/10.1245/s10434-010-0931-5 PMID: 20143267.

30. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012; 151(5):710–6. https://doi.org/10.1016/j.surg.2011.12.017 PMID: 22285778

31. Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. Journal of breast cancer. 2013; 16(2):184–92. https://doi.org/10.4048/jbc.2013.16.2.184 PMID: 23643851

32. Mariani P, Servois V, De Rycke Y, Bennett S, Feron J, Almubarak M, et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. European Journal of Surgical Oncology (EJSO). 2013; 39(12):1377–83. https://doi.org/10.1016/j.ejso.2013.09.021 PMID: 24126165

33. Bacalbas A, Dima SO, Puritan-Pumichescu R, Herlea V, Popescu I. Role of surgical treatment in breast cancer liver metastases: a single center experience. Anticancer research. 2014; 34(10):5563–8. PMID: 25275056

34. Margonis GA, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, et al. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB. 2016; 18(8):700–5. https://doi.org/10.1016/j.hpb.2016.05.014 PMID: 27485066

35. Sadot E, Lee SY, Sotocleous CT, Solomon SB, Gönen M, Kingham TP, et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically
treated patients. Annals of surgery. 2016; 264(1):147. https://doi.org/10.1097/SLA.0000000000001371 PMID: 26445472

36. Ercolani G, Zanello M, Serenari M, Cescon M, Cucchetti A, Ravaioli M, et al. Ten-year survival after liver resection for breast metastases: a single-center experience. Digestive Surgery. 2018; 35(4):372–80. https://doi.org/10.1159/000486523 PMID: 29393171

37. Labgaa I, Slankamenac K, Chadde E, Jibara G, Alsheebek K, Mentha G, et al. Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: a multicentric study. The American Journal of Surgery. 2018; 215(1):125–30. https://doi.org/10.1016/j.amjsurg.2017.09.030 PMID: 29061283

38. Ruiz A, Van Hillegersberg R, Siesling S, Castro-Benitez C, Sebagh M, Wicherts D, et al. Surgical resection versus systemic therapy for breast cancer liver metastases: results of a European case matched comparison. European journal of cancer. 2018; 95:1–10. https://doi.org/10.1016/j.ejca.2018.02.024 PMID: 29579478

39. Sunden M, Hermansson C, Taflin H, Andersson A, Sund M, Hemmingsson O. Surgical treatment of breast cancer liver metastases—A nationwide registry-based case control study. Eur J Surg Oncol. 2020; 46(6):1006–12. Epub 2020/02/27. https://doi.org/10.1016/j.ejso.2020.02.008 PMID: 32098734.

40. He X, Zhang Q, Feng Y, Li Z, Pan Q, Zhao Y, et al. Resection of liver metastases from breast cancer: a multicentre analysis. Clin Transl Oncol. 2020; 22(4):512–21. Epub 2019/06/24. https://doi.org/10.1007/s12094-019-02155-2 PMID: 31230220.

41. Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, et al. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol. 2020; 46(9):1588–95. Epub 2020/04/08. https://doi.org/10.1016/j.ejso.2020.03.214 PMID: 32253074; PubMed Central PMCID: PMC7434685.

42. Ellis OV, Hornock SL, Bohan PMK, Dilday JC, Chang S-C, Bader JO, et al. Impact of Hepatic Metastectomy in the Multimodal Treatment of Metastatic Breast Cancer. Journal of Surgical Research. 2021; 268:650–9. https://doi.org/10.1016/j.jss.2021.07.032 PMID: 34474214

43. Orlandi A, Pontolillo L, Mele C, Pasqualoni M, Pannunzio S, Cannizzaro MC, et al. Liver Metastectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis. J Pers Med. 2021;11(3). Epub 2021/04/04. https://doi.org/10.3390/jpm12010011 PMID: 36055526; PubMed Central PMCID: PMC7998479.

44. ProchÁzkovÁ K, PivoVAR CK, RouSAROV AM, VodiCkA J, HoSeK P, I TR, et al. Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer—19 Years of Experience. In Vivo. 2021; 35(1):417–22. Epub 2021/01/07. https://doi.org/10.21873/in vivo.12273 PMID: 33402491; PubMed Central PMCID: PMC7880733.

45. Fairhurst K, Leopardi L, Satyadas T, Maddern G. The safety and effectiveness of liver resection for breast cancer liver metastases: A systematic review. The Breast. 2018; 30:175–84. https://doi.org/10.1016/j.breast.2016.09.011 PMID: 27764727

46. Feng Y, He X-G, Zhou C-M, Zhang Q-Y, Huang S-Y, Li Z, et al. Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study. The American Journal of Surgery. 2020; 220(4):945–51. https://doi.org/10.1016/j.amjsurg.2020.02.047 PMID: 32145919

47. Spolverato G, Vitale A, Bagante F, Connolly R, Pawlik TM. Liver resection for breast cancer liver metastases. Annals of surgery. 2016; 265(4):792–9. https://doi.org/10.1097/SLA.0000000000001715 PMID: 28266967

48. ProchÁzkovÁ K, PivoVARÁK K, RoušAROVÁ M, VodičkA J, Hošek P, T´ReškOVÁ I, et al. Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer—19 Years of Experience. in vivo. 2021; 35(1):417–22. https://doi.org/10.21873/in vivo.12273 PMID: 33402491

49. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. Journal of clinical oncology. 2010; 28(20):3271–7. https://doi.org/10.1200/JCO.2009.25.9820 PMID: 20498394

50. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast cancer research and treatment. 2009; 115(2):423–8. https://doi.org/10.1007/s10549-008-0086-2 PMID: 18543098

51. Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng C-WD, et al. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. European Journal of Surgical Oncology. 2020; 46(9):1588–95. https://doi.org/10.1016/j.ejso.2020.03.214 PMID: 32253074

52. Treska V, Cerna M, Kylíček T, Treskova I. Prognostic factors of breast cancer liver metastasis surgery. Archives of Medical Science. 2015; 11(3):683. https://doi.org/10.5114/aoms.2015.52376 PMID: 26170865
53. Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers. 2019; 11(9):1341. https://doi.org/10.3390/cancers11091341 PMID: 31514362

54. Xiao Y-b, Zhang B, Wu Y-l. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis. Journal of Zhejiang University-SCIENCE B. 2018; 19(11):829–43. https://doi.org/10.1631/jzus.B1700516 PMID: 30387333

55. Rivera K, Jeyarajah DR, Washington K. Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review. Frontiers in Oncology. 2021; 11:312.

56. Golse N, Adam R. Liver metastases from breast cancer: what role for surgery? Indications and results. Clinical breast cancer. 2017; 17(4):256–65. https://doi.org/10.1016/j.clbc.2016.12.012 PMID: 28196771

57. Rahnemai-Azar AA, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Management of Metastatic Liver Tumors, An Issue of Surgical Oncology Clinics of North America, E-Book. 2020; 30(1):27–37. https://doi.org/10.1016/j.soc.2020.09.003 PMID: 33220807